JP2016536282A - ＰＩ３Ｋα阻害剤を使用する強化された治療レジメン - Google Patents

ＰＩ３Ｋα阻害剤を使用する強化された治療レジメン Download PDF

Info

Publication number
JP2016536282A
JP2016536282A JP2016519762A JP2016519762A JP2016536282A JP 2016536282 A JP2016536282 A JP 2016536282A JP 2016519762 A JP2016519762 A JP 2016519762A JP 2016519762 A JP2016519762 A JP 2016519762A JP 2016536282 A JP2016536282 A JP 2016536282A
Authority
JP
Japan
Prior art keywords
regimen
cancer
administered
inhibitor
pi3kα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016519762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536282A5 (OSRAM
Inventor
ファビアン ゾーレン，
ファビアン ゾーレン，
チラグ パテル，
チラグ パテル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2016536282A publication Critical patent/JP2016536282A/ja
Publication of JP2016536282A5 publication Critical patent/JP2016536282A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016519762A 2013-10-03 2014-10-02 ＰＩ３Ｋα阻害剤を使用する強化された治療レジメン Pending JP2016536282A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361886623P 2013-10-03 2013-10-03
US61/886,623 2013-10-03
US201462054879P 2014-09-24 2014-09-24
US62/054,879 2014-09-24
PCT/US2014/058926 WO2015051193A1 (en) 2013-10-03 2014-10-02 ENHANCED TREATMENT REGIMENS USING PI3Kα INHIBITORS

Publications (2)

Publication Number Publication Date
JP2016536282A true JP2016536282A (ja) 2016-11-24
JP2016536282A5 JP2016536282A5 (OSRAM) 2017-11-02

Family

ID=52779165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519762A Pending JP2016536282A (ja) 2013-10-03 2014-10-02 ＰＩ３Ｋα阻害剤を使用する強化された治療レジメン

Country Status (6)

Country Link
US (1) US20160287601A1 (OSRAM)
EP (1) EP3052493A4 (OSRAM)
JP (1) JP2016536282A (OSRAM)
CN (1) CN105745207A (OSRAM)
CA (1) CA2925523A1 (OSRAM)
WO (1) WO2015051193A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024008799A1 (en) * 2022-07-06 2024-01-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of proliferative glomerulonephritis

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
EP3993786A1 (en) * 2019-07-02 2022-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
WO2025045915A1 (en) * 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
CN120550330B (zh) * 2025-07-29 2025-10-24 四川省肿瘤医院 经皮穴位电刺激调控免疫检查点系统及其方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011022439A1 (en) * 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336723B (es) * 2008-07-11 2016-01-28 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
WO2011017687A1 (en) * 2009-08-06 2011-02-10 Ray Partha S Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
US9403820B2 (en) * 2011-11-11 2016-08-02 Intellikine Llc Kinase inhibitor polymorphs
US8611178B2 (en) * 2011-11-11 2013-12-17 Qualcomm Incorporated Device and method to perform memory operations at a clock domain crossing
CA2856803A1 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011022439A1 (en) * 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024008799A1 (en) * 2022-07-06 2024-01-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of proliferative glomerulonephritis

Also Published As

Publication number Publication date
EP3052493A4 (en) 2017-06-14
EP3052493A1 (en) 2016-08-10
CA2925523A1 (en) 2015-04-09
US20160287601A1 (en) 2016-10-06
CN105745207A (zh) 2016-07-06
WO2015051193A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
JP6130391B2 (ja) Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
JP6047149B2 (ja) 併用の医薬組成物およびその使用
JP6114296B2 (ja) 複数の医薬品を使用した治療レジメン
JP6749858B2 (ja) 複素環式化合物およびそれらの使用
JP6126615B2 (ja) キナーゼ阻害剤の組み合わせおよびそれらの使用
CN103491962B (zh) 激酶抑制剂的组合及其用途
ES2588197T3 (es) Inhibidores de benzoxazol quinasa y métodos de uso
JP2016512835A (ja) キナーゼ阻害剤の組み合わせ及びそれらの使用
JP2016536282A (ja) ＰＩ３Ｋα阻害剤を使用する強化された治療レジメン
CN106456777A (zh) 结合物
EP2914295A1 (en) Treatment of rheumatoid arthritis and asthma using p13 kinase inhibitors
WO2016048982A2 (en) COMBINATION TREATMENT WITH PI3Kα INHIBITORS AND TAXANES
HK1236441A (en) Combination of kinase inhibitors and uses thereof
HK1236441A1 (zh) 激酶抑制劑的組合及其用途
HK1195793B (en) Combination pharmaceutical compositions and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181129